Literature DB >> 16934185

Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead.

Guang-qian Zhou1, Hui-qi Xie, Su-zhen Zhang, Zhi-ming Yang.   

Abstract

OBJECTIVE: To review the recent research progress in dystrophin-related muscular dystrophy includes X-linked hereditary Duchenne and Becker muscular dystrophies (DMD and BMD). DATA SOURCES: Information included in this article was identified by searches of PUBMED and other online resources using the key terms DMD, dystrophin, mutations, animal models, pathophysiology, gene expression, stem cells, gene therapy, cell therapy, and pharmacological. Study selection Mainly original milestone articles and timely reviews written by major pioneer investigators of the field were selected.
RESULTS: The key issues related to the genetic basis and pathophysiological factors of the diseases were critically addressed. The availabilities and advantages of various animal models for the diseases were described. Major molecular and cellular therapeutic approaches were also discussed, many of which have indeed exhibited some success in pre-clinical studies but at the same time encountered a number of technical hurdles, including the efficient and systemic delivery of a functional gene and myogenic precursor/stem cells to repair genetic defects.
CONCLUSIONS: Further understanding of pathophysiological mechanisms at molecular levels and regenerative properties of myogenic precursor/stem cells will promote the development of multiple therapeutic strategies. The combined use of multiple strategies may represent the major challenge as well as the greatest hope for the therapy of these diseases in coming years.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934185

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  4 in total

1.  Nesprin interchain associations control nuclear size.

Authors:  Wenshu Lu; Maria Schneider; Sascha Neumann; Verena-Maren Jaeger; Surayya Taranum; Martina Munck; Sarah Cartwright; Christine Richardson; James Carthew; Kowoon Noh; Martin Goldberg; Angelika A Noegel; Iakowos Karakesisoglou
Journal:  Cell Mol Life Sci       Date:  2012-06-01       Impact factor: 9.261

Review 2.  Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy.

Authors:  Chad D Markert; Anthony Atala; Jennifer K Cann; George Christ; Mark Furth; Fabrisia Ambrosio; Martin K Childers
Journal:  PM R       Date:  2009-06       Impact factor: 2.298

3.  Deletion mutations in Duchenne muscular dystrophy (DMD) in Western Saudi children.

Authors:  Mohammed T Tayeb
Journal:  Saudi J Biol Sci       Date:  2010-04-13       Impact factor: 4.219

4.  Muscular dystrophies at different ages: metabolic and endocrine alterations.

Authors:  Oriana Del Rocío Cruz Guzmán; Ana Laura Chávez García; Maricela Rodríguez-Cruz
Journal:  Int J Endocrinol       Date:  2012-06-03       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.